This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters To the Editor

Reply to “Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.”

Natalie Almeras, PhD; Jean-Pierre Despres, PhD, FAHA; Julie Villeneuve, BPharm; Marie-Franch Demers, BPharm; Roch-Hugo Bouchard, MD

Published: January 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We are grateful to have been given the opportunity to reply to the letter by Karagianis and Dunayevich. We by all means agree that a cross-sectional study has limitations in its design. Our study should be considered as a first attempt to document the metabolic risk profile of patients who had been exposed for the same period of time to 2 atypical antipsychotics: olanzapine and risperidone.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 66

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...